Danish Pharma ALK pays ARS $145m for Neffy nasal spray licensing deal
HQ Team November 13, 2024: ALK-Abelló, the Danish pharma company has acquired exclusive rights to Neffy (epinephrine nasal spray) from ARS Pharmaceuticals for.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team November 13, 2024: ALK-Abelló, the Danish pharma company has acquired exclusive rights to Neffy (epinephrine nasal spray) from ARS Pharmaceuticals for.
ARS Pharmaceuticals, a US-based biopharmaceutical company, got the nation’s drug regulator’s approval for a nasal spray to treat allergic reactions in adult and.